Bristol Myers Squibb (BMY) Other Accumulated Expenses (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Other Accumulated Expenses for 16 consecutive years, with $13.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses fell 22.5% year-over-year to $13.5 billion in Q2 2026; TTM through Jun 2026 was $13.5 billion, a 22.5% decrease from a year earlier, with the FY2025 full-year figure at $17.6 billion, down 3.01% from the prior year.
• Other Accumulated Expenses was $13.5 billion for Q2 2026 at Bristol Myers Squibb, up from $12.6 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $19.3 billion in Q3 2025 and troughed at $12.4 billion in Q1 2022.
• A 5-year average of $15.4 billion and a median of $15.5 billion in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses rose 22.48% in 2024 and dropped 23.6% in 2026, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $14.6 billion in 2022, then rose by 8.9% to $15.9 billion in 2023, then increased by 14.11% to $18.1 billion in 2024, then declined by 3.01% to $17.6 billion in 2025, then declined by 23.36% to $13.5 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $13.5 billion (Q2 2026), $12.6 billion (Q1 2026), and $17.6 billion (Q4 2025), per Business Quant data.